BioProspect keeps the termites at bay
23 April, 2010 by Tim DeanTermites hate it, but home owners may come to love it. It's the termite repellent developed by Australian natural products developer, BioProspect.
BIO 2010: Biotechs ready themselves for recovery
22 April, 2010 by Tim DeanIf you excuse the mixed metaphor, there is light at the end of the tunnel, but we’re not out of the woods yet. That appears to be the sentiment amongst the Australian biotechnology community in the opening months of 2010.
Xenome rustles up another $10 million
22 April, 2010 by Tim DeanQueensland-based private biopharma company, Xenome, has raised $10 million in funds in the form of convertible notes to fuel continued development of its flagship pain drug, Xen2174.
Biotech sector continues strong recovery: PwC
21 April, 2010 by Tim DeanThe biotechnology sector has seen another quarter of strong growth, with the majors - CSL, ResMed and Cochlear - putting in healthy performances, according to PricewaterhouseCoopers' latest BioForum report.
BIO 2010: Queensland fields strong delegation
20 April, 2010 by Staff WritersThe Australian biotechnology industry is warming up for BIO 2010, to be held in Chicago from May 3-6, and Queensland is planning on being well represented at the world's largest biotech convention.
Market Spotlight: LBT Innovations makes bonus $500K from currency hedging
19 April, 2010 by Tim DeanLBT Innovations received two bits of good news today. First is that €2 million came through as a scheduled milestone payment from bioMérieux for LBT's MicroStreak technology.
Australian biotech market watch 16/04/10
16 April, 2010 by Tim DeanThe All Ordinaries dipped back towards the 5,000 mark after seeing well over a month of consistent gains, including pipping 5,000 for the first time since the onset of the global financial crisis.
Market Spotlight: QRxPharma on the up
14 April, 2010 by Tim DeanQRxPharma is another step closer to bringing its immediate release dual-opioid pain therapy, MoxDuoIR, to the market with the completion of one of two pivotal Phase III clinical trials held in the United States.
Insight into soybean could help green crops
13 April, 2010 by Tim DeanSoybean is a remarkable plant, not only a protein rich food crop, but also usable in manifold industrial applications, such as the production of biofuel, emulsifiers, paints and even lipstick.
ChemGenex on path to diagnostic for approval of anti-leukaemia drug
13 April, 2010 by Tim DeanChemGenex working with FDA on validating a diagnostic that will allow anti-leukaemia drug, Omapro, to be approved.
Australian biotech market watch 07/04/10
07 April, 2010 by Tim DeanNews of a further awakening economy and the possibility of more interest rate rises has seen the All Ordinaries nudge up another 11.5 points in morning trading to 4,985, primarily driven by IT and utilities.
Nerve growth factor could yield new breed of painkillers
06 April, 2010 by Staff WritersNerve growth factor an important target for new painkillers, but it's not without its risks, says analysts.
Australian biotechs to benefit from US health care bill
06 April, 2010 by Tim DeanThe new 12 year exclusive market protection on new biologics a boon for biotechnology in Australia.
Bias in scientific publishing rife
01 April, 2010 by Tim DeanA reluctance to publish negative results is leading to a troubling bias in scientific journals.
Clinuvel to commence trial of afamelanotide in the US
30 March, 2010 by Tim DeanPhase II trial to test effectiveness of afamelanotide in treating erythropoietic protoporphyria.
